Axsome Therapeutics Stock Today
| AXSM Stock | USD 126.27 0.37 0.29% |
PerformanceGood
| Odds Of DistressLow
|
Axsome Therapeutics is selling at 126.27 as of the 20th of March 2025; that is 0.29 percent increase since the beginning of the trading day. The stock's lowest day price was 123.51. Axsome Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of November 2015 | Category Healthcare | Classification Health Care |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 48.77 M outstanding shares of which 5.87 M shares are presently shorted by private and institutional investors with about 5.02 trading days to cover. More on Axsome Therapeutics
Moving against Axsome Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Axsome Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Founder, Chairman and CEO | Herriot MD | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAxsome Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Axsome Therapeutics' financial leverage. It provides some insight into what part of Axsome Therapeutics' total assets is financed by creditors.
| |||||
Axsome Therapeutics (AXSM) is traded on NASDAQ Exchange in USA. It is located in One World Trade Center, New York, NY, United States, 10007 and employs 683 people. Axsome Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.14 B. Axsome Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 48.77 M outstanding shares of which 5.87 M shares are presently shorted by private and institutional investors with about 5.02 trading days to cover.
Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Check Axsome Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Axsome Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Axsome Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Axsome Therapeutics. Please pay attention to any change in the institutional holdings of Axsome Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Axsome Ownership Details
Axsome Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alethea Capital Management, Llc | 2024-12-31 | 734.3 K | |
| Amvescap Plc. | 2024-12-31 | 692.5 K | |
| Wellington Management Company Llp | 2024-12-31 | 673.2 K | |
| Perceptive Advisors Llc | 2024-12-31 | 664.1 K | |
| Hood River Capital Management Llc | 2024-12-31 | 644.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 576.9 K | |
| Lazard Asset Management Llc | 2024-12-31 | 537.7 K | |
| Citadel Advisors Llc | 2024-12-31 | 495.4 K | |
| Sofinnova Ventures | 2024-12-31 | 491.7 K | |
| Rtw Investments, Llc | 2024-12-31 | 4.1 M | |
| Vanguard Group Inc | 2024-12-31 | 3.9 M |
Axsome Therapeutics Historical Income Statement
Axsome Stock Against Markets
Axsome Therapeutics Corporate Management
| Hunter Esq | General Secretary | Profile | |
| Amanda PharmD | Senior Development | Profile | |
| Lori MBA | Executive Development | Profile | |
| Kevin PharmD | Ex Strategy | Profile | |
| Mark MA | Chief Officer | Profile |
Already Invested in Axsome Therapeutics?
The danger of trading Axsome Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Axsome Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Axsome Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Axsome Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.99) | Revenue Per Share | Quarterly Revenue Growth 0.66 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.